Innovative Therapeutics TheraSource specializes in developing novel anti-inflammatory molecules targeting serious human diseases such as ischemic acute kidney injury and acute radiation injury, presenting opportunities to collaborate with pharmaceutical and biotech firms focused on inflammation-related therapies.

Research Expertise With a highly educated research team from The Feinstein Institute and a portfolio of 14 patents covering five molecules, TheraSource demonstrates advanced R&D capabilities, making it an attractive partner for organizations seeking cutting-edge anti-inflammatory solutions.

Government Support Receiving a $3M SBIR grant from NIH highlights strong government backing and validation of the company's innovative approach, opening avenues to engage with other government-funded research programs or agencies interested in inflammation and regenerative medicine.

Growing Funding With over $3M in total funding and revenue estimates between $1M to $10M, TheraSource is positioned for expansion and partnerships within the biotech and research services sectors seeking early-stage innovation with commercial potential.

Alignment with Healthcare Trends Targeting inflammatory responses related to acute injuries aligns TheraSource with increasing market demand for specialized therapeutics, offering potential collaboration opportunities with larger healthcare providers, research institutions, and organizations focused on emergency and radiation medicine.